Patients in the LSG group were more sensitive to CZC24832 and Erlotinib AZD2014 has shown antitumour effects as an mTOR inhibitor in a variety of cancers including prostate cancer and HCC [37, 38]. Here, MTOR is linked to prostate cancer.